MALVERN, Penn., Sept. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) said today that it has begun pre-clinical testing of intranasal versions of its influenza vaccines in development, providing a potential alternative to administering these vaccines by injection.
